Randomized, placebo‐controlled, double‐blind trial of clobetasol propionate 0.05% in the treatment of oral lichen planus. (13th March 2018)

• Record Type: Journal Article
• Authors: Arduino, PG; Campolongo, MG; Sciannameo, V; Conrotto, D; Gambino, A; Cabras, M; Ricceri, F; Carossa, S; Broccoletti, R; Carbone, M
• Is Part Of: Oral diseases. Volume 24:Number 5(2018)
• Page Start: 772
• Page End: 777
• Publication Date: 2018-03-13
• Subjects: clobetasol -- oral lichen planus -- outcome -- placebo -- symptomatic; Mouth -- Diseases -- Research -- Periodicals; 617.522
• DOI: 10.1111/odi.12821
• Languages: English
• ISSNs: 1354-523X

Abstract

Abstract : Objective: To perform a randomized, placebo‐controlled, double‐blind study, with a follow‐up period of 6 months, for the use of topical clobetasol in cases of symptomatic oral lichen planus (OLP). Subjects and Methods: Thirty‐two participants were analyzed, with the aims of: (I) to compare the usefulness of topically applied clobetasol propionate 0.05% (mixed with 4% hydroxyethyl cellulose gel) and 4% hydroxyethyl cellulose gel alone (considered as placebo) in the management of OLP; (II) to describe which of them is quicker in decreasing signs and reported symptoms, and (III) which is able to give the proper longer remission in the follow‐up. Results: Symptoms improved in all clobetasol‐treated patients during the first 2 months of therapy, while only 50% of placebo control group ( p = .005) displayed similar results; of the remaining half, 12.5% did experienced a worsening while 37.5% remained stable. Regarding clinical signs, 87.5% of clobetasol‐treated patients improved, while only 62.5% of the placebo‐treated patients had a positive response ( p = .229). Conclusions: It is possible to report that clobetasol, at this dosage, has been more effective than a placebo at provoking symptoms improvement in subjects affected by atrophic‐erosive oral lesions.